Melagatran 是具有口服活性的 thrombin 直接抑制剂，除凝血酶外，它与凝血级联反应中的任何其他酶或纤溶酶没有相互作用。Melagatran 的抗凝血酶作用不需要内源性辅因子，可能有助于减轻内毒素血症的某些破坏作用。 Melagatran 具有预防动脉阻塞的潜能。
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia[1]. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion[2].
[1]. Eriksson M, et al. Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert Opin Investig Drugs. 2000 May;9(5):1129-37. [2]. Mehta JL, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol. 1998 Mar;31(3):345-51.
动态评分
0.0